163217-66-1 Usage
Description
N-4-Benzyloxyphenyl α-Benzilidene Isobutyrylacetamide is a complex organic compound with a unique chemical structure. It is an intermediate of the metabolite of Atorvastin, a drug used for lowering cholesterol levels in patients with hypercholesterolemia. N-4-Benzyloxyphenyl α-Benzilidene Isobutyrylacetamide is characterized by its off-white solid appearance and plays a significant role in the pharmaceutical industry due to its association with Atorvastin.
Uses
Used in Pharmaceutical Industry:
N-4-Benzyloxyphenyl α-Benzilidene Isobutyrylacetamide is used as an intermediate in the synthesis of Atorvastin for the treatment of hypercholesterolemia. As a selective, competitive HMG-CoA reductase inhibitor, Atorvastin effectively lowers both elevated LDL-cholesterol and triglycerides in patients, making it a crucial component in the development and production of this cholesterol-lowering drug.
Used in Metabolite Research:
N-4-Benzyloxyphenyl α-Benzilidene Isobutyrylacetamide is also utilized in the study of the metabolites of Atorvastin, providing valuable insights into the drug's mechanism of action, pharmacokinetics, and potential side effects. Understanding the metabolites can help researchers optimize the drug's efficacy and safety profile, ultimately benefiting patients with hypercholesterolemia.
Check Digit Verification of cas no
The CAS Registry Mumber 163217-66-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,3,2,1 and 7 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 163217-66:
(8*1)+(7*6)+(6*3)+(5*2)+(4*1)+(3*7)+(2*6)+(1*6)=121
121 % 10 = 1
So 163217-66-1 is a valid CAS Registry Number.
InChI:InChI=1/C26H25NO3/c1-19(2)25(28)24(17-20-9-5-3-6-10-20)26(29)27-22-13-15-23(16-14-22)30-18-21-11-7-4-8-12-21/h3-17,19H,18H2,1-2H3,(H,27,29)/b24-17-
163217-66-1Relevant articles and documents
Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound
-
, (2020/12/01)
The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.
Synthesis of deuterium-labeled atorvastatin and its metabolites for use as internal standards in a LC/MS/MS method developed for quantitation of the drug and its metabolites in human serum
Chen, Bang-Chi,Sundeen, Joseph E.,Guo, Peng,Bednarz, Mark S.,Hangeland, Jon J.,Ahmed, Syed Z.,Jemal, Mohammed
, p. 261 - 270 (2007/10/03)
D5-labeled isotopomers of atorvastatin, atorvastatin lactone and its hydroxy metabolites were synthesized as internal standards for use in a LC/MS/MS method developed for the simultaneous quantitative determination of atorvastatin and its hydroxy metabolites in human serum. d5-Atorvastatin and d5-atorvastatin lactone were prepared from d5-aniline whereas their corresponding hydroxy metabolites were synthesized using d5-benzaldehyde.
